The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
 
Begona Mellado
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca Spain; Bayer; Janssen; Pfizer; Pfizer (I); Roche; Roche (I)
Research Funding - Bayer; Janssen; Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I)
 
Daniel E. Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
S Pang
No Relationships to Disclose
 
Yuksul Urun
Honoraria - Amgen; Astellas Medivation; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Medivation; Bayer; Janssen; Sanofi
Speakers' Bureau - Astellas Medivation; Janssen; Novartis; Pfizer; Sanofi
 
Se Hoon Park
Consulting or Advisory Role - Lilly
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Graeme Currie
Employment - Dynavax Technologies; Rainier Therapeutics
Leadership - Rainier Therapeutics
Stock and Other Ownership Interests - Dynavax Technologies; Gilead Sciences; Rainier Therapeutics; Regeneron
Consulting or Advisory Role - Bolt Biotherapeutics; NaNotics
 
Esteban Abella
Employment - Rainier Therapeutics
Leadership - Rainier Therapeutics
Stock and Other Ownership Interests - Rainier Therapeutics
 
Florian D. Vogl
Employment - Rainier Therapeutics
Stock and Other Ownership Interests - Rainier Therapeutics
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Roche
Other Relationship - Bayer (I)